New obesity drug HRS9531 takes on semaglutide in major trial
NCT ID NCT07285902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether a new weekly injection called HRS9531 works better than semaglutide for weight loss in 572 adults with obesity. Participants receive either drug for 52 weeks, and researchers measure changes in body weight, waist size, and BMI. The trial is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS9531 injection
- What this could lead to
- If successful, HRS9531 could offer a new weekly injection option for weight loss that is more effective than current treatments like semaglutide.
- What could go wrong
- This is a phase 3 trial, but results are not yet available. The new drug may not prove superior or could have unexpected side effects compared to semaglutide.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chiness PLA General Hospital
Beijing, Beijing Municipality, 100853, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?